FENNEC PHARMACEUTICALS INC (FENC) — insider trading
Health Care · NASDAQ
FENNEC PHARMACEUTICALS INC (FENC) has 18 reported SEC Form 4 insider transactions in our data, including 2 open-market sales among the most recent 18 (latest 2026-07-01).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-07-01 | Raykov Rosty | Other | Option exercise / conversion (derivative) | 15,597 | $2.45 | $38.2K | Form 4 |
| 2026-07-01 | Raykov Rosty | Other | Open-market sale | 9,599 | $10.41 | $99.9K | Form 4 |
| 2026-07-01 | Raykov Rosty | Other | Option exercise / conversion | 15,597 | $2.45 | $38.2K | Form 4 |
| 2026-07-01 | Raykov Rosty | Other | Grant / award / vesting | 2,778 | $0.00 | $0 | Form 4 |
| 2026-06-30 | Cioffi Christiana Marie | Officer (Chief Strategy Officer) | Grant / award / vesting | 156 | $0.00 | $0 | Form 4 |
| 2026-06-30 | Andrade Robert | Officer (CHIEF FINANCIAL OFFICER) | Grant / award / vesting | 1,703 | $0.00 | $0 | Form 4 |
| 2026-06-30 | Hackman Jeffrey S. | Director, Officer (Chief Executive Officer) | Grant / award / vesting | 1,159 | $0.00 | $0 | Form 4 |
| 2026-06-30 | Sayad Pierre Sargis | Officer (Chief Medical Officer) | Grant / award / vesting | 168 | $0.00 | $0 | Form 4 |
| 2026-06-30 | Evans Terry L | Officer (Chief Commercial Officer) | Grant / award / vesting | 168 | $0.00 | $0 | Form 4 |
| 2026-06-10 | RALLIS CHRIS A | Director | Grant / award / vesting (derivative) | 20,000 | $8.70 | $174.0K | Form 4 |
| 2026-06-10 | Islam Khalid | Director | Grant / award / vesting (derivative) | 25,000 | $8.70 | $217.5K | Form 4 |
| 2026-06-10 | Cook Jodi A | Director | Grant / award / vesting (derivative) | 20,000 | $8.70 | $174.0K | Form 4 |
| 2026-06-10 | Brughera Marco Maria | Director | Grant / award / vesting (derivative) | 20,000 | $8.70 | $174.0K | Form 4 |
| 2026-06-01 | Raykov Rosty | Director | Option exercise / conversion (derivative) | 15,597 | $2.45 | $38.2K | Form 4 |
| 2026-06-01 | Raykov Rosty | Director | Open-market sale | 9,747 | $9.62 | $93.8K | Form 4 |
| 2026-06-01 | Raykov Rosty | Director | Option exercise / conversion | 15,597 | $2.45 | $38.2K | Form 4 |
| 2026-05-31 | Raykov Rosty | Director | Grant / award / vesting | 2,778 | $0.00 | $0 | Form 4 |
| 2026-05-31 | Cioffi Christiana Marie | Officer (Chief Strategy Officer) | Grant / award / vesting | 156 | $0.00 | $0 | Form 4 |
Ask the chat about FENC's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: FENNEC PHARMACEUTICALS INC (FENC).
Last updated 2026-07-01 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.